NQO1 and acute pancreatitis: Dunnione, an orally administered substrate of NAD(P)H quinone oxidoreductase 1 (NQO1), is reported to increase cellular NAD+ levels in multiple tissues by accelerating the oxidation of NADH to NAD+, and has beneficial effects on various diseases, such as acute pancreatitis, cisplatin-induced tissue injury, and adriamycin-induced cardiac dysfunction [19,20,21].